2,3,4,6-四甲基-1-氟苯 | 319-91-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,3,4,6-四甲基-1-氟苯
• 中文别名: 2,3,4,6-四甲基氟苯
• 英文名称: Tetramethyl-fluor-benzol
• 英文别名: 2-fluoro-1,3,4,5-tetramethyl-benzene；2-Fluor-1,3,4,5-tetramethyl-benzol；2-Fluoro-1,3,4,5-tetramethylbenzene
• CAS: 319-91-5
• 化学式: C₁₀H₁₃F
• 分子量: 152.212
• InChiKey: WGOOHIBXEKJTGZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-溴-2,4,6-三甲基氟苯 在 乙醚 、 magnesium 作用下， 生成 2,3,4,6-四甲基-1-氟苯
  参考文献：
  名称：

  Grassini et al., Gazzetta Chimica Italiana, 1956, vol. 86, p. 1138,1145

  摘要：

  DOI：

文献信息

• ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
  申请人：Universal Display Corporation

  公开号：US20190248818A1

  公开（公告）日：2019-08-15

  A compound comprising a first ligand L A of Formula I, is disclosed. In the structure of Formula I, ring A is a 5-membered or 6-membered carbocyclic or heterocyclic ring; Z 1 -Z 4 are each independently C or N; at least two consecutive Z 1 -Z 4 are C, and are fused to a structure of or Y 1 and Y 2 are each independently O, S, Se, CRR′, SiRR′, or GeRR′; each R A , R B , R C , R, and R′ is a hydrogen or a substituent; and any two substituents may be joined or fused together to form a ring. In the compound, L A is complexed to a metal M by the dashed lines in Formula I to form a five-membered chelate ring, and M has an atomic weight greater than 40. Organic light emitting devices and consumer products containing the compounds are also disclosed.

  揭示了一种包括第一配体LA的化合物。在公式I的结构中，环A是一个5元或6元碳环或杂环；Z1-Z4分别独立地是C或N；至少两个连续的Z1-Z4是C，并且与结构oforY1和Y2熔合；Y1和Y2分别独立地是O、S、Se、CRR′、SiRR′或GeRR′；每个RA、RB、RC、R和R′是氢或取代基；任意两个取代基可以连接或熔合在一起形成环。在该化合物中，LA通过公式I中的虚线与金属M络合形成一个五元螯合环，且M的原子量大于40。还揭示了含有这些化合物的有机发光器件和消费品。
• PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE
  申请人：Chakravarty Sarvajit

  公开号：US20130172320A1

  公开（公告）日：2013-07-04

  This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及吡啶并[4,3-b]吲哚和吡啶并[3,4-b]吲哚衍生物。本公开还提供了包含该化合物的制药组合物，以及使用该化合物治疗各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• COMPOUNDS AND METHODS OF TREATING HYPERTENSION
  申请人：Protter Andrew Asher

  公开号：US20140303144A1

  公开（公告）日：2014-10-09

  Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α 2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α 2B . The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.

  本文介绍了氢化吡啶[4,3-b]吲哚、吡啶[3,4-b]吲哚和氮杂七环[4,5-b]吲哚。这些化合物可以与肾上腺素受体α2B结合并对其产生拮抗作用。这些化合物还可以与肾上腺素受体α2B结合并对其产生拮抗作用。这些化合物可以用于治疗，例如：（i）降低血压和/或（ii）促进肾脏血流和/或（iii）减少或抑制钠的重吸收。这些化合物还可以用于治疗对降低血压有反应或预计会有反应的疾病或病况。特别描述了这些化合物用于治疗心血管和肾脏疾病。
• FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE
  申请人：Chakravarty Sarvajit

  公开号：US20130210803A1

  公开（公告）日：2013-08-15

  This disclosure is directed to fused tetracyclic pyrido[4,3-b]indoles and pyrido[3,4-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及熔合四环吡啶[4,3-b]吲哚和吡啶[3,4-b]吲哚。还提供了包含这些化合物的制药组合物，以及使用这些化合物进行多种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• COMPOUNDS AND METHODS OF TREATING DIABETES
  申请人：Protter Andrew Asher

  公开号：US20140228353A1

  公开（公告）日：2014-08-14

  Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor α 2A . The compounds may also bind to and are an antagonist of the adrenergic receptor α 2B ; or the compounds are not antagonists of the adrenergic receptor α 2B and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.

  介绍了氢化吡咯[4,3-b]吲哚、吡咯[3,4-b]吲哚和氮杂七环[4,5-b]吲哚。这些化合物可以结合并拮抗肾上腺素α2A受体。这些化合物也可以结合并拮抗肾上腺素α2B受体；或者这些化合物不是肾上腺素α2B受体的拮抗剂，并且这些化合物与第二种预计可以降低血压的药物一起使用。这些化合物可以用于治疗，例如调节血糖水平，增加胰岛素分泌并治疗对胰岛素产生增加反应的疾病或状况。特别描述了使用这些化合物治疗2型糖尿病的方法。